IL162822A0 - Treatment of male sexual dysfunction - Google Patents
Treatment of male sexual dysfunctionInfo
- Publication number
- IL162822A0 IL162822A0 IL16282203A IL16282203A IL162822A0 IL 162822 A0 IL162822 A0 IL 162822A0 IL 16282203 A IL16282203 A IL 16282203A IL 16282203 A IL16282203 A IL 16282203A IL 162822 A0 IL162822 A0 IL 162822A0
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- sexual dysfunction
- male sexual
- male
- dysfunction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0202282.0A GB0202282D0 (en) | 2002-01-31 | 2002-01-31 | Treatment of male sexual dysfunction |
| PCT/IB2003/000140 WO2003064402A1 (en) | 2002-01-31 | 2003-01-20 | Treatment of male sexual dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL162822A0 true IL162822A0 (en) | 2005-11-20 |
Family
ID=9930155
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16282203A IL162822A0 (en) | 2002-01-31 | 2003-01-20 | Treatment of male sexual dysfunction |
| IL162822A IL162822A (en) | 2002-01-31 | 2004-07-01 | Use of a selective oxytocin receptor antagonist in the manufacture of medicaments for the treatment of premature ejaculation, an assay method for identifying such agonists and pharmaceutical compositions consisting of one or more of said antagonists and one or more pdeis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL162822A IL162822A (en) | 2002-01-31 | 2004-07-01 | Use of a selective oxytocin receptor antagonist in the manufacture of medicaments for the treatment of premature ejaculation, an assay method for identifying such agonists and pharmaceutical compositions consisting of one or more of said antagonists and one or more pdeis |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1470115A1 (ko) |
| JP (3) | JP2005525321A (ko) |
| KR (2) | KR100829262B1 (ko) |
| CN (1) | CN100500658C (ko) |
| AU (1) | AU2003201471B2 (ko) |
| BR (1) | BR0307337A (ko) |
| CA (1) | CA2474590A1 (ko) |
| GB (1) | GB0202282D0 (ko) |
| HK (1) | HK1073109A1 (ko) |
| IL (2) | IL162822A0 (ko) |
| MX (1) | MXPA04007434A (ko) |
| NZ (1) | NZ546408A (ko) |
| PL (1) | PL371415A1 (ko) |
| TW (1) | TW200302732A (ko) |
| WO (1) | WO2003064402A1 (ko) |
| ZA (1) | ZA200405208B (ko) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3646871A1 (en) * | 2018-10-30 | 2020-05-06 | SEROJAC PME Handels GmbH | Treatment and prevention of premature ejaculation (pe) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| GB9114760D0 (en) | 1991-07-09 | 1991-08-28 | Pfizer Ltd | Therapeutic agents |
| GB9119704D0 (en) | 1991-09-14 | 1991-10-30 | Pfizer Ltd | Therapeutic agents |
| GB9121028D0 (en) | 1991-10-03 | 1991-11-13 | Pfizer Ltd | Therapeutic agents |
| GB9126260D0 (en) | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
| GB9213623D0 (en) | 1992-06-26 | 1992-08-12 | Pfizer Ltd | Therapeutic agents |
| GB9218322D0 (en) | 1992-08-28 | 1992-10-14 | Pfizer Ltd | Therapeutic agents |
| CA2151821A1 (en) * | 1992-12-23 | 1994-07-07 | Kevin Gilbert | Hydantoin and succinimide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists |
| CA2118756A1 (en) * | 1993-03-12 | 1994-09-13 | Anthony M. Demarco | Process for the synthesis of substituted amide derivatives of piperizinylcamphorsulfonyl oxytocin antagonists |
| GB0007884D0 (en) | 2000-03-31 | 2000-05-17 | Pfizer Ltd | Diphenyl ether compounds useful in therapy |
| US20020028799A1 (en) * | 2000-07-06 | 2002-03-07 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
-
2002
- 2002-01-31 GB GBGB0202282.0A patent/GB0202282D0/en not_active Ceased
-
2003
- 2003-01-20 PL PL03371415A patent/PL371415A1/xx not_active Application Discontinuation
- 2003-01-20 CN CNB038030535A patent/CN100500658C/zh not_active Expired - Lifetime
- 2003-01-20 EP EP03700164A patent/EP1470115A1/en not_active Withdrawn
- 2003-01-20 NZ NZ546408A patent/NZ546408A/en not_active IP Right Cessation
- 2003-01-20 BR BR0307337-8A patent/BR0307337A/pt not_active IP Right Cessation
- 2003-01-20 MX MXPA04007434A patent/MXPA04007434A/es active IP Right Grant
- 2003-01-20 CA CA002474590A patent/CA2474590A1/en not_active Abandoned
- 2003-01-20 KR KR1020047011672A patent/KR100829262B1/ko not_active IP Right Cessation
- 2003-01-20 IL IL16282203A patent/IL162822A0/xx unknown
- 2003-01-20 WO PCT/IB2003/000140 patent/WO2003064402A1/en active Application Filing
- 2003-01-20 JP JP2003564025A patent/JP2005525321A/ja not_active Ceased
- 2003-01-20 AU AU2003201471A patent/AU2003201471B2/en not_active Expired
- 2003-01-20 KR KR1020077029747A patent/KR20080011232A/ko not_active Application Discontinuation
- 2003-01-27 TW TW092101731A patent/TW200302732A/zh unknown
-
2004
- 2004-06-30 ZA ZA2004/05208A patent/ZA200405208B/en unknown
- 2004-07-01 IL IL162822A patent/IL162822A/en active IP Right Grant
-
2005
- 2005-07-11 HK HK05105801.3A patent/HK1073109A1/xx not_active IP Right Cessation
-
2010
- 2010-03-30 JP JP2010079241A patent/JP2010209075A/ja not_active Withdrawn
-
2013
- 2013-02-28 JP JP2013038357A patent/JP2013151511A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW200302732A (en) | 2003-08-16 |
| KR20040079958A (ko) | 2004-09-16 |
| HK1073109A1 (en) | 2005-09-23 |
| GB0202282D0 (en) | 2002-03-20 |
| ZA200405208B (en) | 2005-08-31 |
| NZ546408A (en) | 2007-10-26 |
| IL162822A (en) | 2010-11-30 |
| CN1625553A (zh) | 2005-06-08 |
| KR20080011232A (ko) | 2008-01-31 |
| BR0307337A (pt) | 2004-12-07 |
| CA2474590A1 (en) | 2003-08-07 |
| JP2010209075A (ja) | 2010-09-24 |
| JP2005525321A (ja) | 2005-08-25 |
| CN100500658C (zh) | 2009-06-17 |
| KR100829262B1 (ko) | 2008-05-13 |
| PL371415A1 (en) | 2005-06-13 |
| JP2013151511A (ja) | 2013-08-08 |
| EP1470115A1 (en) | 2004-10-27 |
| MXPA04007434A (es) | 2004-10-11 |
| WO2003064402A1 (en) | 2003-08-07 |
| AU2003201471B2 (en) | 2009-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL377729A1 (pl) | Sposób leczenia dysfunkcji seksualnej | |
| IL153492A0 (en) | Treatment of male sexual dysfunction | |
| AU2003248888A8 (en) | Peptide composition for treatment of sexual dysfunction | |
| HK1040901A1 (en) | Treatment of female sexual dysfunction | |
| GB0225908D0 (en) | Treatment of female sexual dysfunction | |
| ZA200410009B (en) | Compositions and methods for ameliorating of human female sexual dysfunction | |
| AU2003219981A1 (en) | Benzimidazole-derivatives for the treatment of sexual dysfunction | |
| AU2002238106A1 (en) | Melanocortin metallopeptides for treatment of sexual dysfunction | |
| GB2408558B (en) | Treatment of pipes | |
| IL162154A0 (en) | Prostagandin composition for the treatment of erectile dysfunction | |
| EP1648430A4 (en) | TREATMENT FOR EJACULATIO PRAECOX | |
| GB2386555B (en) | Treatment of female sexual dysfunction | |
| IL166273A0 (en) | Methods of treatment of male erectile dysfunction | |
| IL162455A0 (en) | Compounds for the treatment of sexual dysfunction | |
| IL155775A0 (en) | Treatment of male sexual dysfunction | |
| PL362980A1 (en) | Treatment of sexual dysfunction | |
| AU2003260818A8 (en) | Treatment of immune system dysfunction | |
| AP2004003174A0 (en) | Treatment of water | |
| IL162822A0 (en) | Treatment of male sexual dysfunction | |
| GB0120679D0 (en) | Treatment of male sexual dysfunction | |
| GB0106167D0 (en) | Treatment of male sexual dysfunction | |
| GB0108483D0 (en) | Treatment of male sexual dysfunction | |
| GB0108730D0 (en) | Treatment of male sexual dysfunction | |
| GB0316673D0 (en) | Treatment of female sexual dysfunction | |
| GB0221712D0 (en) | Methods of treatment |